OTCQB:PVCT - Post by User
Post by
mplauton Apr 08, 2014 5:15pm
297 Views
Post# 22427009
Schedule and Expectations in April and May for PVCT
Schedule and Expectations in April and May for PVCT
The next 2 months have important events scheduled and other important events expected.
April 6 - Poster at the American Association of Cancer Research (AACR) meeting. It was written by a member of the Moffitt Cancer Research Institute, an independent center of cancer research and treatment. In a press release describing the presentation was included the following (emphasis added): Dr. Pilon-Thomas of Moffitt stated, “These data are exciting and illustrate successful translation of our pre-clinical work in mice to clinical results in melanoma patients. With only 8 patients we've been able to clearly observe statistically significant increases in beneficial T cell populations in peripheral blood. Ironically, the original aim of the trial to assess tumor-infiltrating lymphocytes was thwarted when biopsies of patient tumors collected just 7-14 days after PV-10 injection no longer contained viable tumor tissue. We are following up both the human data and continuing to design more experiments in mice to better explain the systemic immune effects elicited by PV-10 ablation.” This confirms something the company said earlier: When you inject them with PV-10, the tumors go away.
April 11 - At HemOnc Today, PV-10 will be an integral part of Session 4: Local and Regional Therapy.
Before or About May 24 - Reply from the FDA to Provectus' application for BreakThrough Designation.
May 30 - 2 posters in the Poster Highlights session at the American Society of Clinical Oncology (ASCO) meeting. One by Moffitt and the other by Dr Agarwala of St Lukes. ASCO is the year's premier event. The poster highlights sessions are a notch above the regular poster sessions.
EXPECTATIONS IN ADDITION: An uplisting of the stock on either NASDAQ or NYSE/MKT
Possibilities: News about PH-10, license(s) for foreign sales